Cyclophosphamide supply shortage reported in Europe

The European Medicines Agency (EMA) has reported a supply shortage of cyclophosphamide, a chemotherapy medicine used to treat several types of cancer and some autoimmune conditions.

Cyclophosphamide has been used in cancer care for many years and remains part of treatment regimens for cancers including lymphoma, breast cancer, and small cell lung cancer.

According to the EMA, the shortage is currently being monitored at European level. Information has been shared with national authorities, healthcare professionals, and patients about the cause of the shortage, which countries may be affected, and how the situation is being managed.

In lung cancer, cyclophosphamide may be used as part of the CAV regimen (cyclophosphamide, doxorubicin and vincristine) for people with small cell lung cancer, particularly when the disease returns after initial treatment.

While cyclophosphamide is not commonly used in modern treatment for non small cell lung cancer, supply shortages of established chemotherapy medicines can still affect treatment planning across cancer services.

Healthcare professionals may consider alternative treatment approaches if needed while supply is being managed.

The EMA continues to monitor the situation and provide updates.